Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is N/A as of Tuesday, October 6, 2026.
NET PROFIT MARGIN
N/A
Obsidian Therapeutics Inc.
Market Cap
$14.42M
Net Profit Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.44M
Net Profit Margin
-39.61%
TTM Avg
-209.93%
3Y Avg
-392.71%
5Y Avg
-532.46%
Market Cap
$14.94M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-2405.08%
Market Cap
$15.43M
Net Profit Margin
-153.28%
TTM Avg
-93.42%
3Y Avg
-97.51%
5Y Avg
-105.13%
Market Cap
$13.77M
Net Profit Margin
-651.27%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.72M
Net Profit Margin
-8716.77%
TTM Avg
-1649.40%
3Y Avg
-960.30%
5Y Avg
-749.49%
Market Cap
$15.42M
Net Profit Margin
-3011.52%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-79.84%
Market Cap
$13.56M
Net Profit Margin
-3972.87%
TTM Avg
-1209.50%
3Y Avg
-3598.61%
5Y Avg
-2399.08%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.42M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | -39.61% | -209.93% | -392.71% | -532.46% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.94M | 0.00% | 0.00% | 0.00% | -2405.08% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.43M | -153.28% | -93.42% | -97.51% | -105.13% |
| IN8bio, Inc. (INAB)vs › | $13.91M | 0.00% | 0.00% | 0.00% | 0.00% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.77M | -651.27% | 0.00% | 0.00% | 0.00% |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | -8716.77% | -1649.40% | -960.30% | -749.49% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | -3011.52% | 0.00% | 0.00% | -79.84% |
| Optimi Health Corp. (OPTH)vs › | $13.56M | -3972.87% | -1209.50% | -3598.61% | -2399.08% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.83M | -3575.07% | -1754.85% | -877.42% | -584.95% |
Operating Margin
N/A
Net Profit Margin
N/A
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
